Sector News

Fresenius moves forward with two U.S. expansions after killing Akorn deal

April 11, 2019
Life sciences

Fresenius Kabi missed an opportunity to quickly bulk up in sterile manufacturing when its $5 billion deal to buy Akorn imploded last year, but its organic expansion efforts in the U.S. are moving forward. One of those, which will add 450 jobs, has reached a milestone.

The German drugmaker last week held a so-called topping off ceremony, a traditional construction milestone, for a $100 million project in Wilson, North Carolina, the North Carolina Biotechnology Centers reports. The expansion, which promises to provide 445 jobs to the 100 it already has at the site, is slated to be completed in 2022. Fresenius makes prefilled syringes at the site, which it acquired from Becton Dickinson in 2017.

Fresenius announced the expansion in 2017, just months after it initially committed to buying U.S.-based sterile drug competitor Akorn. The Akorn deal would have significantly expanded its production, with two plants in the U.S. and one in India. That deal went south last year, however, after Fresenius uncovered quality manufacturing issues at Akorn that it said it was unaware of when it agreed to buy the sterile drug producer. After a trial, a judge said Fresenius was within in its rights to cancel the deal.

Fresenius also has an expansion project running concurrently at its sterile injectables manufacturing site in Melrose Park, Illinois, near its U.S. headquarters in Lake Zurich, Illinois. That $250 million, decade-long project includes new buildings for aseptic filling lines, expanded lyophilization capabilities and formulation areas, as well as a warehouse. There also will be an administration building, laboratories, office space and cafeteria space, all of it tied to the existing manufacturing site and intended as a showcase for customers.

Fresenius in February reported (PDF) 2018 revenues of €33.5 billion, up 6% in constant currency. Sales in North America, which make up about 40% of its business, were up 3%.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.